Deletion of carboxypeptidase N delays onset of experimental cerebral malaria

Parasite Immunology

Volumn 34, Issue 8-9, 2012, Pages 444-447

  Darley, M M ^a   Ramos, T N ^a   Wetsel, R A ^b   Barnum, S R ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Carboxypeptidases; Cerebral malaria; Complement anaphylatoxins

Indexed keywords

ARGININE CARBOXYPEPTIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MALARIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL CEREBRAL MALARIA; EXPERIMENTAL INFECTION; GENE DELETION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; WILD TYPE;

ANIMALS; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; LYSINE CARBOXYPEPTIDASE; MALARIA, CEREBRAL; MICE; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TIME FACTORS;

MUS;

EID: 84864775734     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2012.01376.x     Document Type: Article

References (26)

1. Patel SN, Berghout J, Lovegrove FE, et al. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J Exp Med 2008; 205: 1133-1143.
2. Conroy A, Serghides L, Finney C, et al. C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS One 2009; 4: e4953.
3. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES & Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol 2009; 46: 2753-2766.
4. Ramos TN, Darley M, Bilker O, et al. The membrane attack complex of complement is required for the development of experimental cerebral malaria. J Immunol 2011; 186: 6657-6660.
5. Skidgel RA & Erdos EG. Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator. Int Immunopharmacol 2007; 7: 1888-1899.
6. Matthews KW, Mueller-Ortiz SL & Wetsel RA. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol Immunol 2004; 40: 785-793.
7. Oshima G, Kato J & Erdos EG. Plasma carboxypeptidase N, subunits and characteristics. Arch Biochem Biophys 1975; 170: 132-138.
8. Sato T, Miwa T, Akatsu H, et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-1058.
9. Koomen JM, Li D, Xiao LC, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005; 4: 972-981.
10. Bokisch VA, Muller-Eberhard HJ & Cochrane CG. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 1969; 129: 1109-1130.
11. Mueller-Ortiz SL, Wang D, Morales JE, Li L, Chang JY & Wetsel RA. Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock. J Immunol 2009; 182: 6533-6539.
12. Sinden RE, Butcher GA & Beetsma AL. Maintenance of the Plasmodium berghei life cycle. Methods Mol Med 2002; 72: 25-40.
13. Wohler JE, Smith SS, Zinn KR, Bullard D & Barnum SR. gd T cells in experimental autoimmune encephalomyelitis: early trafficking events and cytokine requirements. Eur J Immunol 2009; 39: 1516-1526.
14. Odya CE, Wilgis FP, Walker JF & Oparil S. Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421). J Lab Clin Med 1983; 102: 714-721.
15. Marceau F, Barabe J, St-Pierre S & Regoli D. Kinin receptors in experimental inflammation. Can J Physiol Pharmacol 1980; 58: 536-542.
16. Regoli D & Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
17. Bhoola KD, Figueroa CD & Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
18. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ & Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
19. Amante FH, Haque A, Stanley AC, et al. Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol 2010: 185: 3632-3642.
20. Noda M, Sasaki K, Ifuku M & Wada K. Multifunctional effects of bradykinin on glial cells in relation to potential anti-inflammatory effects. Neurochem Int 2007; 51: 185-191.
21. Noda M, Kariura Y, Pannasch U, et al. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem 2007; 101: 397-410.
22. Skidgel RA. Structure and function of mammalian zinc carboxypeptidases. In Hooper NM (ed.): Zinc Metalloproteases in Health and Disease. London, Taylor and Francis Ltd., 1996: 241-283.
23. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
24. Campbell W, Okada N & Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-167.
25. Campbell WD, Lazoura E, Okada N & Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
26. Fernandez D, Pallares I, Vendrell J & Aviles FX. Progress in metallocarboxypeptidases and their small molecular weight inhibitors. Biochimie 2010; 92: 1484-1500.